journal article·2026-07

Lysosomal disruption elicits immunogenic cell death: A saponin-nanoaluminum adjuvant for enhanced cancer immunotherapy

Jingsong Lu, Jing Yu, Zhenhu Guo, Sumei Chen, Ying Li, Qing Sun, Yao Ying, Juan Li, Liang Qiao, Jingwu Zheng, Yen Wei, Lingyun Zhao, Shenglei Che

Publisher page

Abstract

Inducing lysosomal membrane permeabilization (LMP) represents an alternative therapeutic strategy that bypasses conventional genetic or protein targets and triggers cell death by physically tumor disrupting. Herein, QS-21, an FDA-approved saponin with membrane-disruptive capability was loaded onto an aluminum-based adjuvant (denoted as QS-NanoAlum) to induce LMP effects and trigger tumor immunogenic cell death (ICD) through a "self-lysis" mechanism. Leveraging its positive surface charge, intratumorally administered QS-NanoAlum could be easily adhered to tumor cell membranes, facilitating efficient cellular internalization. Within the acidic lysosomal environment, QS-NanoAlum underwent degradation and subsequently released QS-21, leading to LMP effect and the cytosolic leakage of hydrolytic enzymes. The released hydrolases and QS-21 would further inflict collateral damage to cellular structures and organelles, including the plasma membrane, nucleus, mitochondria, and endoplasmic reticulum, which ultimately culminated in ICD. Notably, excess QS-NanoAlum could efficiently adsorb the released tumor-associated protein antigens (TAAs) during ICD, forming an antigen depot at the injection site that sustained long-term immune stimulation. Our in vivo studies also demonstrated that QS-NanoAlum significantly suppressed tumor growth and enhanced immune cell infiltration into tumor tissues. Finally, this strategy that physically disrupting the cellular "recycling center" to provoke cell disintegration and elicit robust ICD, offering a promising paradigm for cancer immunotherapy. STATEMENT OF SIGNIFICANCE: Conventional cancer therapies target specific mutations but are limited by tumor heterogeneity and resistance. We introduce a new paradigm that physically disrupts tumor cells via lysosomal membrane permeabilization (LMP), bypassing molecular targets. Our system, QS-NanoAlum (QS-21 loaded to an aluminum adjuvant), triggers immunogenic cell death through a "self-lysis" mechanism. Positively charged QS-NanoAlum is internalized and degrades in acidic lysosomes, releasing QS-21 to induce LMP. Released hydrolases cause widespread organelle damage, leading to robust immunogenic cell death. Excess QS-NanoAlum adsorbs tumor-associated antigens, forming a sustained immune depot. In vivo, QS-NanoAlum suppresses tumor growth and enhances immune infiltration, validating its potential for cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cell death mechanisms and regulation · Autophagy in Disease and Therapy · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Tetrahedral deoxyribonucleic acid-engineered multivalent lysosome-targeting chimera for enhanced and dual membrane protein degradation10.1021/acsnano.5c03556 ↗
2. Designed endocytosis-inducing proteins degrade targets and amplify signals10.1038/s41586-024-07948-2 ↗
3. pH-triggered aggregation of polylysine nanoparticles enhances TNF-α siRNA delivery for rheumatoid Arthritis therapy10.1002/adfm.202516705 ↗
4. Lysosome-targeting protein degradation through endocytosis pathway triggered by polyvalent nano-chimera for AD therapy10.1002/adma.202411061 ↗
5. HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma10.1038/cddis.2013.263 ↗
6. A bifunctional lysosome-targeting Chimera nanoplatform for tumor-selective protein degradation and enhanced cancer immunotherapy10.1002/adma.202417942 ↗
7. Lysosome targeted nanoparticle aggregation reverses immunosuppressive tumor microenvironment for cancer immunotherapy10.1002/adma.202412730 ↗
8. Harnessing endocytic pH gradients for cascaded formation of intracellular condensates to inhibit autophagy: a pathway to cancer therapy10.1016/j.nantod.2024.102317 ↗
9. Ultrasound-triggered lysosomal alkalinization to block autophagy in tumor therapy10.1016/j.biomaterials.2025.123250 ↗
10. Targeted crystallization of mixed-charge nanoparticles in lysosomes induces selective death of cancer cells10.1038/s41565-020-0643-3 ↗
11. Provoking lysosome disruption via In situ engineered double-network assemblies for targeted cancer cell death10.1021/acsnano.5c00268 ↗
12. Nanomedicine in cancer therapy10.1038/s41392-023-01536-y ↗
13. Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specific therapy10.1039/C7CS00471K ↗
14. Local destruction of tumors for systemic immunoresponse: engineering antigen-capturing nanoparticles as stimulus-responsive immunoadjuvants10.1021/acsami.1c21946 ↗
15. Genetically edited Cascade nanozymes for cancer immunotherapy10.1021/acsnano.4c01229 ↗
16. Mn(iii)-mediated carbon-centered radicals generate an enhanced immunotherapeutic effect10.1039/D3SC03635A ↗
17. Oxygen-driven prussian blue nanomotor promotes cancer immunotherapy by disrupting redox state-induced tumor disulfide death10.1016/j.jcis.2025.138404 ↗
18. Ultrasound-powered piezocatalytic nanomotors with dual-mode synergistic/cascade propulsion reprogram hypoxic tumor-associated macrophages for enhanced cancer immunotherapy10.1016/j.cej.2025.162107 ↗
19. pH-ultrasensitive polyester nanoprobe for high-contrast tumor imaging with superior biocompatibility
20. Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection10.1038/s41551-025-01343-6 ↗
21. Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates10.1038/s41551-024-01285-5 ↗
22. Targeted delivery of hemostats to complex bleeding wounds with magnetic guidance for instant hemostasis10.1016/j.cej.2021.130916 ↗
23. A near-infrared light-driven Janus nanomotor for deep tumor penetration and enhanced tumor immunotherapy10.1039/D4CC03445G ↗
24. In situ polymerization-mediated antigen presentation10.1021/jacs.3c02682 ↗
25. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity10.1038/s41563-018-0256-5 ↗
26. Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy10.1038/s41565-025-02071-3 ↗
27. The inhibition of death receptor mediated apoptosis through lysosome stabilization following internalization of carboxyfullerene nanoparticles10.1016/j.biomaterials.2011.02.008 ↗
28. Targeted self-assembly of renal clearable Cu2-xSe to induce lysosome swelling for multimodal imaging guided photothermal/chemodynamic synergistic therapy10.1002/adfm.202208354 ↗
29. Intracellular condensates of oligopeptide for targeting lysosome and addressing multiple drug resistance of cancer
30. A. von dem Bussche, boron nitride nanosheets can induce water channels across lipid bilayers leading to lysosomal permeabilization10.1002/adma.202103137 ↗
31. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
32. Tumour-derived microparticles obtained through microwave irradiation induce immunogenic cell death in lung adenocarcinoma10.1038/s41565-025-01922-3 ↗
33. Near-infrared II phototherapy induces deep tissue immunogenic cell death and potentiates cancer immunotherapy10.1021/acsnano.9b06040 ↗
34. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy10.1039/D1NR05512G ↗
35. Biomaterials that induce immunogenic cell death10.1002/smtd.202300204 ↗
36. Immunologically effective chiral polymers to potentiate anti-cancer immune responses10.1021/polymscitech.5c00110 ↗
37. A hypoxia-activated copper ion nanoexchanger for cancer immunotherapy by in situ precise production of immunogenic cell death inducer10.1016/j.cclet.2025.111404 ↗
38. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence10.1016/j.jconrel.2025.113979 ↗
39. Saponin-mediated cell membrane interference nanomedicine potentiates tumor chemo-immunotherapy via a perforin-granzyme-like mechanism10.1039/D5BM00564G ↗
40. Saponins: properties, applications and processing10.1080/10408390600698197 ↗
41. Efficient drug supply in stem cell cytosol via pore-forming saponin nanoparticles promotes in vivo osteogenesis and bone regeneration10.1016/j.biomaterials.2023.122342 ↗
42. Elucidation of the pathway for biosynthesis of saponin adjuvants from the soapbark tree10.1126/science.adf3727 ↗
43. A review of ultrasound-assisted extraction for plant bioactive compounds: phenolics, flavonoids, thymols, saponins and proteins10.1016/j.foodres.2022.111268 ↗
44. The Achilles’ heel of cancer: targeting tumors via lysosome-induced immunogenic cell death10.1038/s41419-022-04912-8 ↗
45. NanoAlum based delivery system to formulate in-situ vaccine for personalized breast cancer immunotherapy10.26599/NR.2025.94907642 ↗
46. Dihydroartemisinin loaded layered double hydroxide nanocomposites for tumor specific photothermal–chemodynamic therapy10.1039/D0TB01964J ↗
47. Manganese-based layered double hydroxide nanoparticles as a T1-MRI contrast agent with ultrasensitive pH response and high relaxivity10.1002/adma.201700373 ↗
48. Confined synthesis of carbon nitride in a layered host matrix with unprecedented solid-State quantum yield and stability10.1002/adma.201704376 ↗
49. Coupling probiotics with 2D CoCuMo-LDH nanosheets as a tumor-microenvironment-responsive platform for precise NIR-II photodynamic therapy10.1002/adma.202211205 ↗